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Acinetobacter baumannii is one of the most important opportunistic pathogens that
causes serious health care associated complications in critically ill patients. In the current
study we report on the diversity of the clinical multi-drug resistant (MDR) A. baumannii
in Kuwait by molecular characterization. One hundred A. baumannii were isolated from
one of the largest governmental hospitals in Kuwait. Following the identification of the
isolates by molecular methods, the amplified blaOXA-51-like gene product of one isolate
(KO-12) recovered from blood showed the insertion of the ISAba19 at position 379
in blaOXA-78. Of the 33 MDR isolates, 28 (85%) contained blaOXA-23, 2 (6%) blaOXA-24
and 6 (18%) blaPER-1 gene. We did not detect blaOXA-58, blaVIM, blaIMP, blaGES, blaVEB,
and blaNDM genes in any of the tested isolates. In three blaPER-1 positive isolates the
genetic environment of blaPER-1 consisted of two copies of ISPa12 (tnpiA1) surrounding
the blaPER-1 gene on a highly stable plasmid of ca. 140-kb. Multilocus-sequence typing
(MLST) analysis of the 33 A. baumannii isolates identified 20 different STs, of which
six (ST-607, ST-608, ST-609, ST-610, ST-611, and ST-612) were novel. Emerging STs
such as ST15 (identified for the first time in the Middle East), ST78 and ST25 were also
detected. The predominant clonal complex was CC2. Pulsed-field gel electrophoresis
and MLST defined the MDR isolates as multi-clonal with diverse lineages. Our results
lead us to believe that A. baumannii is diverse in clonal origins and/or is undergoing
clonal expansion continuously while multiple lineages of MDR A. baumannii circulate in
hospital ward simultaneously.
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Introduction
Acinetobacter baumannii is one of the most important opportunistic pathogens that causes
outbreaks in hospitals and serious health care associated complications in critically ill patients.
The ability to acquire multiple antibiotic resistance genes and to survive in inanimate
environments are important characteristics of this nosocomial pathogen (Corbella et al.,
2000). The guidelines for the antimicrobial therapy for the treatment of Acinetobacter
infections comprise of broad spectrum cephalosporins, the β-lactamase inhibitor sulbactam,
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quinolones, carbapenems, amikacin, doxycycline, and
minocycline. In the case of infections caused by multi-
drug resistant (MDR) strains, tigecycline and colistin are
recommended as the last therapeutic options either alone or
in combination therapy (Talbot et al., 2006). Recently some
A. baumannii isolates have become resistant to almost all the
currently available antibiotics including colistin (Magiorakos
et al., 2012). Acquisition of resistance to colistin is mostly due
to modiﬁcations of the lipopolysaccharide (LPS) biosynthesis
pathway (Potron et al., 2015).
In A. baumannii carbapenem-hydrolysing class D
β-lactamases (CHDLs) are major contributors to antibiotic
resistance (Poirel and Nordmann, 2006). These enzymes
are predominantly expressed by transmissible blaOXA genes
including: blaOXA-23-like, blaOXA-24-like, blaOXA-58-like,
blaOXA-143-like, and the intrinsic blaOXA-51-like genes typically
present in A. baumannii (Evans and Amyes, 2014). Over
expression of OXA enzymes is often associated with the presence
of an insertion element upstream of the gene (Turton et al.,
2006). It has been reported that if blaOXA-51 is to contribute
to β-lactam resistance, insertion element ISAba1 upstream of
the gene is required to act as a strong transcriptional promoter
(Ruiz et al., 2007). The acquired carbapenem resistance may
also be associated with the production of metallo-β-lactamases
such as IMP-, VIM-, and NDM-like carbapenemases (Poirel and
Nordmann, 2006).
In addition to OXA and metallo-β-lactamases, resistance to
cephalosporins inA. baumannii can be caused by chromosomally
encoded AmpC enzymes, referred to as ADC cephalosporinases,
through their overexpression in the presence of ISAba1 upstream
of the gene (Peleg et al., 2008; Bonnin et al., 2013), or by
acquisition of extended spectrum β-lactamases (ESBLs) such
as GES-, VEB-, and PER-like enzymes (Nemec et al., 2008).
The blaPER-1 gene has been detected in ceftazidime-resistant
A. baumannii strains worldwide (Peleg et al., 2008) as part of
a composite-transposon called Tn1213, associated with ISPa12
(Bonnin et al., 2013). Recently we identiﬁed an A. baumannii
isolate from Kuwait that contained a blaPER-1 gene in a composite
transposon made of two copies of ISPa12 (Opazo et al., 2014)
prompting an increase in the minimum inhibitory concentration
(MIC) of the cephalosporins and probably contributing to the
mobilization of this gene.
It is crucial to sustain the eﬀectiveness of the limited choices
of antimicrobial agents we have left. This can be achieved by
means of epidemiological studies and the understanding of the
evolution of endemic and epidemic strains by characterizing the
MDR isolates (Hamouda et al., 2010). Most common methods
for epidemiology studies used for A. baumannii are pulsed-
ﬁeld gel electrophoresis (PFGE), multilocus-sequence typing
(MLST), ampliﬁed fragment length polymorphism (AFLP)
analysis, and other PCR- and sequence-based methods as
well as whole genome sequencing analysis (Wright et al.,
2014).
The main aim of this study was to investigate the diversity of
MDR A. baumannii in Kuwait by molecular characterization of
the clinical isolates. Our results will provide a platform for future
evolutionary studies in this region and beyond.
Materials and Methods
Bacterial Strains
One hundred A. baumannii isolates were collected arbitrarily
from patients who were admitted to Al-Amiri Hospital from
2011 until 2012. Al-Amiri hospital is a tertiary health care
provider with a 500 bed capacity. The average number of
specimens processed every day in the microbiology laboratory
varies from 500 to 700 which includes samples from out-patient
and in-patient specialists units. A database was created based
on the patients’ records containing information such as age,
sex, hospital location of care and type of specimen. Specimens
were processed by clinical staﬀ members of the diagnostic
microbiology laboratory using standard protocols. All isolates
were identiﬁed initially by using conventional microbiological
techniques based on colony morphology, biochemical analysis
and by using the VITEK2 system (VITEK AMS; bioMérieux
VITEK Systems Inc., Hazelwood, MO, USA). The isolates were
stored in 10% skimmed milk at −70◦C.
The identiﬁcation was then carried out in our laboratory
at species level by gyrB multiplex PCR (Higgins et al., 2007,
2010) and conﬁrmed by sequencing of an internal portion of the
rpoB gene (Gundi et al., 2009). The blaOXA-51−like gene was also
ampliﬁed, puriﬁed, and sequenced (Heritier et al., 2005).
Susceptibility Testing
Antibiotic susceptibility testing was performed by the disk
diﬀusion method when applicable following the Clinical and
Laboratory Standards Institute [CLSI] (2012) recommendations.
The bacterial suspension (the ﬁnal turbidity of a 0.5
McFarland standard) was spread over the Mueller-Hinton agar
homogenously and the antimicrobial disks were dispensed onto
the agar plates using the disk dispenser and incubated overnight
at 37◦C. These antibiotic agents tested were Amikacin (30 μg),
Gentamycin (10 μg), Ampicillin/sulbactam (10 μg/10 μg),
Cefotaxime (30 μg), Ceftazidime (30 μg), Ceﬁpime (30 μg),
Cefoxitin (30 μg), Piperacillin (30 μg), Piperacillin/tazobactam,
Ciproﬂoxacin (5 μg), Tigecycline (15 μg), Meropenem (10 μg),
and Imipenem (10 μg). The diameter of zone of inhibition
was measured (mm) for all and interpreted as recommended
by the Clinical and Laboratory Standards Institute [CLSI]
(2012) guidelines. There was no CLSI guideline available for
tigecycline, therefore we used the breakpoints recommended for
Enterobacteriaceae by European Committee on Antimicrobial
Susceptibility Testing [EUCAST] (2014). The MIC was
determined only for some of the antibiotics by the agar
dilution method following the CLSI recommendations (Table 1).
Colistin susceptibility was calculated by broth microdilution
technique which is considered the gold standard (Hindler and
Humphries, 2013). The criteria for classifying the isolates as
MDR was based on recommendations of Magiorakos et al.
(2012).
Detection and Identification of blaOXA Genes
blaOXA-like genes including blaOXA-51, blaOXA-23, blaOXA-24, and
blaOXA-58 were ampliﬁed as described previously (Woodford
et al., 2006). Ampliﬁed DNA fragments were puriﬁed with
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TABLE 1 | Antimicrobial susceptibility of the MDR isolates in this study.
Antibiotic Breakpoints (mg/L) % S % I % R MIC50 (mg/L) MIC90 (mg/L)
Amikacin 16 ≤ I ≥ 64 52 24 24 8 128
Ampicillin/sulbactam 8/4 ≤ I ≥ 32/16 30 18 52 8 128
Piperacillin/tazobactam 16/4 ≤ I ≥ 128/4 12 9 79 128 256
Cefotaxime 8 ≤ I ≥ 64 0 0 100 128 256
Ceftazidime 8 ≤ I ≥ 32 9 12 79 128 256
Ciprofloxacin 1 ≤ I ≥ 4 18 18 64 1 4
Imipenem 4 ≤ I ≥ 16 55 0 45 8 16
Tigecycline S ≤ 1 R > 2 100 0 0 0.25 0.25
Colistin 2 ≤ I ≥ 4 97 0 3 1 2
Qiaquick PCR puriﬁcation kits (Qiagen, Valencia, CA, USA).
Both strands of the ampliﬁcation products were sequenced with
an ABI 3100 sequencer (Applied Biosystems Life Technologies,
Thermo Fisher Scientiﬁc Inc., Grand Island, NY, USA) and
were analyzed using the National Center for Biotechnology
Information web site1.
Detection and Identification of ESBLs and
Carbapenemases
The presence of the blaADC-like gene (Ruiz et al., 2007) and the
identiﬁcation of any insertion element upstream of it, was carried
out as described previously (Opazo et al., 2012). The detection of
ESBLs (blaPER-like, blaGES-like, blaVEB-like, blaIMP-like, blaNDM-like,
blaVIM-like) was performed by PCR according to Opazo et al.
(2012).
Characterisation of the Genetic Environment
of blaPER-1
In order to investigate the immediate genetic context of the
blaPER-1 gene, inverse-PCR and sequencing were performed with
some modiﬁcations (Opazo et al., 2012). Brieﬂy, the whole DNA
was restricted with EcoRI endonuclease for 2 h at 37◦C and then
circularized using the T4 ligase for 16 h at room temperature
following the manufacturer’s recommendations (New England
Biolabs, Hertfordshire, UK). To determine the downstream
context of blaPER-1 the circularized DNA was used as a
template for a PCR using the primers invPER-F (5′-GCCGAACC
AATGAAGCTATCATTGCGCAGG-3′) and invPER-R (5′-AA
TTTGCTCTTTTAACAGTGGGGATTGCGCTG-3′). The PCR
products obtained were sequenced and analyzed. The upstream
region of blaPER-1 gene was characterized as before (Opazo et al.,
2012).
Plasmid Analysis
Plasmids were extracted by the use of a commercial kit following
the manufacturer’s instructions and separated by PFGE using a
CHEF-DRII system (Bio-Rad, Hercules, CA, USA). The size of
the only plasmid detected was calculated employing the Quantity
one software v4.6.1 (Bio-Rad). The plasmid was extracted from
agarose using a commercial kit (Qiagen) and used as a template
for PCR with the blaPER-1 and blaOXA-51 primers to determine
1www.ncbi.nlm.nih.gov
whether blaPER-1 is plasmid-borne and to conﬁrm the product
was free of chromosomal contamination. The contribution of
the blaPER-1 gene to ceftazidime-resistance was analyzed by
curing experiment at 45◦C according to Opazo et al. (2014). For
plasmid curing experiments a single colony was streaked onto a
MacConkey agar plate every day for 30 days and incubated at
47◦C. The susceptibility to ceftazidime wasmeasured by diﬀusion
test (Kirby–Bauer method) and the presence of blaPER-1 was
detected by PCR as explained earlier.
Multilocus-Sequence Typing
Genomic DNA was extracted by using the Wizard genomic DNA
puriﬁcation kit (promega, UK) followed by PCR of the seven
housekeeping genes as described by the Institut Pasteur web site.
The internal fragments of protein encoding housekeeping genes
were ampliﬁed, sequenced, and analyzed according to Diancourt
et al. (2010). The isolates were assigned to sequence types (STs)
using the Institut Pasteur web site2.
eBURST Analysis
eBURST analysis was conducted to investigate the evolutionary
relationships and clonal complexes (CCs) within the isolates,
using the software on the eBURST website3.
Pulsed-Field Gel Electrophoresis
Chromosomal DNA was prepared and digested with ApaI
(Promega, Southampton, UK) according toMiranda et al. (1996).
DNA fragments were separated on 1%, w/v agarose gels in
0.5× TBE buﬀer at 14◦C using a CHEF DRII apparatus (Bio-
Rad) with 6 V/cm, pulsed from 5 to 35 s for 24 h. Gels were
stained with ethidium bromide and were scanned using the
Bio-Rad Gel Doc software image capturing system. The Dice
coeﬃcient was used to calculate similarities, and the unweighted
pair groupmethod using average linkages (UPGMA)was used for
cluster analysis with BioNumerics software v. 7.1 (AppliedMaths,
St Martens-Latem, Belgium). Isolates that clustered together
with a similarity of >85% were considered to belong to the
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Results
Antimicrobial Resistance
Of the 100 isolates tested 33 (33%) were resistant to at least three
or more classes of antibiotic (Table 1). The majority of isolates
were collected from urine samples (33%) followed by wound
samples (18%; Figure 1). Only isolate KO-116 conferred reduced
sensitivity to colistin (MIC 2.5 mg/L) as well as all other types of
antibiotics tested. KO-116 was isolated from a 62 years-old male
patient admitted to the ICU ward.
Detection and Identification of blaOXA Genes
All the 100 isolates contained a blaOXA-51-like gene. The ampliﬁed
product of the blaOXA-51-like gene for one isolate (KO-12)
recovered from blood of a patient with chronic renal failure
did not show the expected product size of 353 bp. Sequencing
the blaOXA-51-like variant showed the insertion of ISAba19 at
position 380 in blaOXA-78. KO-12 contained blaOXA-24 and had
an intermediate resistance to ciproﬂoxacin and was sensitive to
carbapenems, colistin, and tigecycline. Therefore since this isolate
did not match our MDR criteria it was not included in this study.
Of the 33 MDR A. baumannii isolates, 28 (85%) contained
blaOXA-23 and 2 (6%) blaOXA-24. We did not detect blaOXA-58
genes in any of the tested isolates. blaVIM, blaIMP, blaGES and
blaNDM, blaVEB genes were not identiﬁed. All the 33 isolates
contained a blaADC-like gene.
Detection and Identification of blaPER-1
In three out of six blaPER-1 positive isolates (KO-5, 22, and 31) the
genetic environment of blaPER-1 consisted of two copies of ISPa12
(tnpiA1) surrounding the blaPER-1 gene with a spacer region of
154 bp in both extremes. blaPER-1 was located on a plasmid of
ca. 140-kb. The plasmid was not deleted after 30 days of curing
and by PCR the blaPER-1 gene was detected indicating that the
plasmid was highly stable. The novel transposon has the accession
number: KF978125. As for the other three cephalosporine
resistant (ceftazidime MIC >256 mg/l) blaPER-1 positive isolates
(KO-4, 34, and 82) we did not detect ISPa12 upstream the
gene.
Characterization of A. baumannii Isolates by
MLST
Multilocus-sequence typing analysis of the 33 A. baumannii
isolates identiﬁed 20 diﬀerent STs. Of the 20 STs determined by
Institut Pasteur scheme, six were novel. They included ST-607,
ST-608, ST-609, ST-610, ST-611, and ST-612. The predominant
ST was ST-2, which was comprised of six isolates (18%), followed
by ST-25 and ST-32, both with four isolates (12%). Other less
common STs were ST-78 with two isolates (6%), ST-158 also
comprising of two isolates (9%) and 15 STs were presented only
once in the data set (Figure 1). The isolates from urine samples
were the most diverse belonging to nine diﬀerent STs. Of the 11
urine isolates, (18% [n = 2]) were ST-2, (18% [n= 2]) were ST-25
while the other seven isolates were of other STs.
eBURST Analysis
Bymeans of the eBURST algorithm, the 33 isolates were clustered
into at least four CCs and 11 singletons (Figure 1). The largest
CC, CC2 comprised 18% (n = 7) of the isolates, while 23.3% of
the isolates belonged to ST-2 (n = 6) or ST-98 (n = 1).
Pulsed-Field Gel Electrophoresis
Pulsed-ﬁeld gel electrophoresis analysis suggested the presence of
ﬁve major clusters with two or more isolates (Figure 2). Only
FIGURE 1 | eBURST figure comparing the data of the tested isolates with all of the database. Assigned numbers for the new STs, ST-607, ST-608, ST-609,
ST-610, ST-611, and ST-612. The corresponding sequence types are shown beside each isolate number. CCs assigned by eBURST analysis as indicated.
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FIGURE 2 | Dendogram illustrating the PFGE patterns of A. baumannii isolates after restriction with ApaI enzyme. PFGE settings: Similarity coefficient
Dice. Optimization: 1.5%, Tolerance: 1.5%, Tolerance change: 1%, Uncertain bands: Ignore, Relaxed doublet matching. Clustering method: UPGMA. Active zones:
[0.0–100.0%].
three isolates displayed identical PFGE patterns. Interestingly
they were ST25 containing the blaPER-1 gene (KO 4, 34, 82)
indicating the possibility of a pseudo outbreak. From the
dendogram we can conclude that not all the isolates belonging to
the same ST necessarily shared identical PFGE pattern. However,
none of the identical PFGE patterns were from diﬀerent STs. In
addition the presence or absence of blaOXA-23 is neither associated
with the PFGE patterns nor with STs. We can also observe that in
most cases the CC correlated with the PFGE lineages. Four of the
isolates were not typeable by PFGE.
Discussion
In the current study we report on the diversity of the clinical
MDRA. baumannii isolated from one of the largest governmental
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hospitals in Kuwait. MDR isolates pose a great risk to the
treatment of patients in Al-Amiri hospital. Following the
identiﬁcation of the isolates by molecular methods, the ampliﬁed
blaOXA-51-like gene product of one isolate (KO-12) recovered
from blood showed the insertion of the ISAba19 at position
379 in blaOXA-78 similarly to a previous report (Zander et al.,
2013). As suggested, failure to detect the correct blaOXA-51-
like product should not be a suﬃcient reason to exclude the
isolate as A. baumannii. However, since this isolate could not be
classiﬁed as MDR (resistance to antibiotics in more than three
antimicrobial categories), it was therefore excluded from this
study.
We employed PFGE and MLST to type the isolates as both
techniques have high discriminatory powers. MLST is suitable
to trace the evolutionary history of A. baumannii and to build
population genetic structure by separating epidemiologically
unrelated isolates (Bartual et al., 2005) and PFGE typing is
a useful epidemiological tool for outbreak analysis. According
to our ﬁndings the 33 MDR A. baumannii comprised of 20
diﬀerent STs and at least three CCs of which six novel STs
were identiﬁed. Noticeably emerging STs (Villalón et al., 2011;
Giannouli et al., 2013) such as ST15, ST78, and ST25 were
detected. Themost common STwas ST-2 and CC2was the largest
CC. The detection of six novel STs supports the notion that
A. baumannii is diverse in clonal origins and/or is undergoing
clonal expansion continuously. Due to the close proximity of
Kuwait to other countries in the Gulf region, it is not surprising
to detect common STs: ST-2 and ST-25 have been previously
identiﬁed in Saudi Arabia (Aly et al., 2014) and in Yemen
(Bakour et al., 2014). Moreover; ST-2 is known as an endemic
strain in European countries including Italy and Spain (Villalón
et al., 2011; Mezzatesta et al., 2014). We also detected the novel
international CC32 with known epidemic potential (Da Silva
et al., 2014). It has been shown that strains assigned to sequence
types ST2, ST25, and ST78 produce bioﬁlm more eﬃciently and
are able to form a robust bioﬁlm pellicle at the air-liquid interface
of the culture medium (Giannouli et al., 2013).
Our study group is too small to ﬁnd statistical correlation
between either the STs andward to suggest endemicity or between
the sample type and the STs. The most alarming aspect in the
ICU was the isolation of KO-116 belonging to ST-2 with reduced
sensitivity to colistin (MIC = 2.5 mg/L) which is known to
have the potential to become endemic and pose a greater risk to
treating infected patients (Giannouli et al., 2013). In this study
we also detected ST15 for the ﬁrst time in the Middle East.
According Diancourt et al. (2010), the rapid clonal expansion of
ST15 and its evolutionary success is due to the fact that almost all
A. baumannii belonging to ST15 are MDR.
The blaOXA-23 gene is considered a virulence biomarker and
a signiﬁcant cause of carbapenem resistance worldwide (Luo
et al., 2015) and is either located on the chromosome or on
plasmids. Transposons Tn2006, Tn2007, and Tn2008 have been
identiﬁed to contain blaOXA-23 (Mugnier et al., 2010). In our
study blaOXA-23 was also the most common oxacillinase gene
identiﬁed, similar to other Gulf countries (Zowawi et al., 2015).
Our results show that there was a strong correlation between
the presence of blaOXA-23 and MDR phenotype. However, the
presence of this gene was not associated with STs indicating
that blaOXA-23 is most likely present on a mobile element. In
contrast to previous reports on the prevalence of blaOXA-58,
blaGES blaIMP, and blaVIM in A. baumannii (Al-Sweih et al., 2012;
Bonnin et al., 2013; Zowawi et al., 2015), we did not detect any
of the mentioned resistance genes among the 33 MDR isolates.
These variations might be attributed to diﬀerences in antibiotic
treatment strategies at hospitals which in turn may inﬂuence the
evolutionary direction of A. baumannii.
Another interesting ﬁnding was a novel genetic transposon-
like structure related to blaPER-1 in A. baumannii. Three isolates
(KO-5, KO-22, and KO-31) were highly resistant to ceftazidime
(MIC >256 mg/l). The PFGE patterns of the three isolates were
not identical, however, they belonged to ST2. In these isolates
the ISAba1 element was detected upstream the blaADC-like gene,
which has been described as the most common mechanism
of ceftazidime resistance (Peleg et al., 2008). Nevertheless,
blaADC-like gene was not the exclusive mechanism of resistance
to ceftazidime. The second mechanism was the presence of ESBL
blaPER-1 detected on a plasmid of ca. 140-kb. Previously The
blaPER-1 gene has been associated with ISPa12 upstream, which
increases its expression, and bracketed downstream by ISPa13,
comprising the transposon Tn1213 (Poirel et al., 2011). However,
in this study the blaPER-1 gene was surrounded by two copies of
ISPa12 (TnpA1) representing a novel genetic structure harboring
this enzyme. The genetic environment of blaPER-1 was composed
by two copies of ISPa12, ﬂanking either side of the ESBL gene
with a spacer region of 154 bp at both extremities (accession
no. KF978125). The ISPa12 element was originally identiﬁed in
Pseudomonas aeruginosa species, which may suggest that the
blaPER-1 gene may have been acquired from this microorganism.
The unsuccessful plasmid curing experiments implied that the
large 140-kb plasmid is highly stable. Nevertheless the presence
of two copies of ISPa12 conﬁrms the remarkable ability of
A. baumannii to utilize insertion sequences to increase the
expression of resistance genes. This characteristic may be a
contributing factor to instigate A. baumannii as a threatening
nosocomial pathogen. PFGE analysis revealed that the presence
of the blaPER-1 gene is not limited to a certain pattern which
correlates with the MLST results.
PFGE showed that within the time line of our research
diﬀerent genotypes of MDR A. baumannii circulated in the
hospital. Only three of the isolates containing the blaPER-1 gene
showed identical PFGE patterns which leads us to believe there is
a possibility of a pseudo outbreak.
In Kuwait cephalosporins are widely used to treat infections;
therefore it is important to monitor and to control the spread of
horizontal transfer by administering the correct antibiotic and
preventing the spread of resistant strains among hospitalized
patients.
Conclusion
While PFGE proﬁles did not always correlate with the MLST,
nevertheless both techniques deﬁned the MDR isolates as multi-
clonal circulating in hospital ward simultaneously. The outcome
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of our study provides a baseline for future longitudinal research
whereby transitory and endemic strains can be identiﬁed.
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